Want to see KR:002390 full AI Analyst Report?
Handok, Inc. (002390) AI Stock Analysis
Handok, Inc.
(Korea Exchange:002390)
The score is held down primarily by weak financial quality—ongoing net losses, negative free cash flow, and higher leverage—despite a notable TTM revenue rebound and improved operating profitability. Technicals also remain bearish with negative momentum and price below major moving averages, while valuation support is limited by a negative P/E, partially offset by a moderate dividend yield.
Handok, Inc. (002390) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- KRW 106.66B
- Dividend Yield
- 2.44%
- Average Volume (3M)
- 8,876
- Price to Earnings (P/E)
- -10.8
- Beta (1Y)
- -0.01
- Revenue Growth
- 7.15%
- EPS Growth
- 59.41%
- Country
- KR
- Employees
- 951
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Pharmaceuticals
Handok, Inc. Business Overview & Revenue Model
Company Description
HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glu...
Handok, Inc. Financial Statement Overview
Summary
Operations are improving with a sharp TTM revenue rebound and a recovery to positive operating/EBITDA profitability versus the 2024 trough, but net income remains negative. Cash flow is still a major weakness (TTM and 2025 free cash flow negative) and leverage has increased (debt-to-equity ~1.49 in TTM), limiting flexibility.
Income Statement
44NeutralBalance Sheet
46NeutralCash Flow
32Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 560.89B | 535.14B | 507.36B | 522.74B | 543.76B | 517.64B |
| Gross Profit | 158.46B | 144.47B | 157.41B | 151.37B | 173.71B | 167.55B |
| EBITDA | 39.94B | 26.80B | -20.82B | 2.76B | 50.26B | 49.37B |
| Net Income | -9.37B | -2.15B | -52.56B | -28.80B | 10.68B | 3.29B |
Balance Sheet | ||||||
| Total Assets | 779.69B | 790.75B | 788.56B | 790.34B | 871.11B | 841.56B |
| Cash, Cash Equivalents and Short-Term Investments | 25.80B | 28.07B | 56.04B | 20.06B | 39.85B | 35.44B |
| Total Debt | 376.66B | 379.43B | 373.39B | 300.01B | 298.29B | 258.39B |
| Total Liabilities | 524.61B | 512.43B | 499.49B | 449.71B | 489.25B | 457.57B |
| Stockholders Equity | 253.29B | 276.61B | 287.26B | 338.73B | 379.81B | 384.00B |
Cash Flow | ||||||
| Free Cash Flow | -8.04B | -9.88B | -22.19B | 9.80B | -13.22B | -6.23B |
| Operating Cash Flow | 5.06B | 3.98B | -2.79B | 35.98B | 30.52B | 37.23B |
| Investing Cash Flow | -14.39B | -22.37B | -31.29B | -49.72B | -63.50B | -45.70B |
| Financing Cash Flow | -7.40B | -9.74B | 70.39B | -6.39B | 39.83B | 15.25B |
Handok, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:002390, the sentiment is Negative. The current price of 8210.00 is below the 20-day moving average (MA) of 8409.50, below the 50-day MA of 8856.20, and below the 200-day MA of 9458.11, indicating a bearish trend. The MACD of -115.40 indicates Negative momentum. The RSI at 41.24 is Neutral, neither overbought nor oversold. The STOCH value of 51.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:002390.
Handok, Inc. Peers Comparison
Overall Rating
KR:23408069Neutral
KR:00385068Neutral
KR:00272062Neutral
KR:18575057Neutral- KR:00239044Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| KR:234080 | 69Neutral | KRW 162.74B | 6.25 | ― | 5.23% | 1.00% | -47.42% |
| KR:003850 | 68Neutral | KRW 702.03B | 9.47 | ― | 1.93% | 6.39% | 29.21% |
| KR:002720 | 62Neutral | KRW 68.11B | 13.94 | ― | 0.90% | 8.02% | -23.36% |
| KR:185750 | 57Neutral | KRW 831.41B | 10.46 | ― | 0.79% | 7.15% | 29.88% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| KR:002390 | 44Neutral | KRW 113.00B | -10.81 | ― | 2.44% | 7.15% | 59.41% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KR:002390 | Handok, Inc. | 8210.00 | -2848.67 | -25.76% | |
| KR:002720 | KUKJE PHARMA Co., Ltd. | 3345.00 | -779.62 | -18.90% | |
| KR:003850 | Boryung Corporation | 8310.00 | -461.66 | -5.26% | |
| KR:023910 | Daihan Pharmaceutical Co., Ltd. | 24750.00 | -2950.58 | -10.65% | |
| KR:185750 | Chong Kun Dang Pharmaceutical Corp. | 63100.00 | -19812.28 | -23.90% | |
| KR:234080 | JW LIFESCIENCE CORPORATION | 10510.00 | -2697.57 | -20.42% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026